Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
A new study pinpoints just three genes—CYP2C19, SLCO1B1, and CYP2C9—that could cover nearly all older Chinese patients exposed to multiple medications with genetic prescribing guidance. Analyzing over 3.3 million patient records, researchers found 1 in 5 older adults received at least two drugs where genetics matter. A targeted three-gene panel could streamline pharmacogenomic testing and help reduce adverse drug reactions in this population.
Researchers at Peking University Health Science Center have identified a compact set of three genes that could form the backbone of pharmacogenomic testing for older adults in China. By analyzing over 3.3 million patient-year records from national health insurance claims (2015–2017), the team found that 1 in 5 older adults (65+) were exposed to at least two medications with established genetic prescribing guidance in a single year.
The three genes—CYP2C19, SLCO1B1, and CYP2C9—collectively covered at least 98% of those records, with statins (like atorvastatin) and proton pump inhibitors (like pantoprazole) being the most common drug classes involved. Because a person's genetic profile is stable over time, a one-time test could inform prescribing decisions across multiple care episodes.
By the Numbers:
Why it matters: As polypharmacy grows among aging populations, targeted genetic testing could reduce harmful drug reactions and improve prescribing precision—at a potentially lower cost than current approaches. Prospective studies are still needed to confirm clinical benefit in real-world practice.
